PMID- 36066075
OWN - NLM
STAT- MEDLINE
DCOM- 20230125
LR  - 20230202
IS  - 2167-9223 (Electronic)
IS  - 2167-8421 (Linking)
VI  - 24
IP  - 1-2
DP  - 2023 Feb
TI  - Prevalence of depression in amyotrophic lateral sclerosis/motor neuron disease: 
      multi-attribute ascertainment and trajectories over 30 months.
PG  - 82-90
LID - 10.1080/21678421.2022.2096410 [doi]
AB  - Objective: Evidence is equivocal about the prevalence of depression in 
      amyotrophic lateral sclerosis (ALS). This study uses a multi-attribute 
      ascertainment of the prevalence of depression and examines this prevalence over 
      time. Methods: Patients with ALS were recruited into the Trajectories of Outcome 
      in Neurological Conditions (TONiC-ALS) study. Caseness was identified by the 
      Modified-Hospital Anxiety and Depression Scale (M-HADS). In addition, 
      participants provided data on co-morbidities and medication use. A combination of 
      the three was used to derive the estimate for the prevalence of depression, 
      treated or untreated. Longitudinal data were analyzed by trajectory analysis of 
      interval level M-HADS-Depression data. Results: Among 1120 participants, the mean 
      age was 65.0 years (SD 10.7), 60.4% male, and the median duration since diagnosis 
      was 9 months (IQR 4-24). Caseness of probable depression at baseline, defined by 
      M-HADS-Depression, was 6.45% (95%CI: 5.1-8.0). Taken together with antidepressant 
      medication and co-morbidity data, the prevalence of depression was 23.1% (95%CI: 
      20.7-25.6). Of those with depression, 17.8% were untreated. Trajectory analysis 
      identified three groups, one of which contained the most cases; the level of 
      depression for each group remained almost constant over time. Conclusion: 
      Depression affects almost a quarter of those with ALS, largely confined to a 
      single trajectory group. Prevalence estimates based on screening for current 
      depressive symptoms substantially under-estimate the population experiencing 
      depression. Future prevalence studies should differentiate data based on current 
      symptoms from those including treated patients. Both have their place in 
      assessing depression and the response by the health care system, including 
      medication, depending upon the hypothesis under test.
FAU - Young, C A
AU  - Young CA
AUID- ORCID: 0000-0003-1745-7720
AD  - Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UK.
AD  - Institute of Systems, Molecular and Integrative Biology, University of Liverpool, 
      Liverpool, UK.
FAU - Ealing, J
AU  - Ealing J
AD  - Greater Manchester Centre for Clinical Neurosciences, Salford, UK.
FAU - McDermott, C J
AU  - McDermott CJ
AUID- ORCID: 0000-0002-1269-9053
AD  - Sheffield Institute for Translational Neuroscience, Sheffield, UK.
FAU - Williams, T L
AU  - Williams TL
AD  - Royal Victoria Infirmary, Newcastle upon Tyne, UK.
FAU - Al-Chalabi, A
AU  - Al-Chalabi A
AUID- ORCID: 0000-0002-4924-7712
AD  - Department of Basic and Clinical Neuroscience, King's College London, Maurice 
      Wohl Clinical Neuroscience Institute, London, UK.
AD  - Department of Neurology, King's College Hospital, London, UK.
FAU - Majeed, T
AU  - Majeed T
AD  - Lancashire Teaching Hospital, Preston, UK.
FAU - Talbot, K
AU  - Talbot K
AD  - Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
FAU - Harrower, T
AU  - Harrower T
AD  - University of Exeter, Exeter Medical School, Exeter, UK.
FAU - Faull, C
AU  - Faull C
AD  - LOROS Hospice, Leicester, UK.
FAU - Malaspina, A
AU  - Malaspina A
AD  - UCL Queen Square Institute of Neurology, London, UK.
FAU - Annadale, J
AU  - Annadale J
AD  - Hywel Dda University Health Board, Wales, UK, and.
FAU - Mills, R J
AU  - Mills RJ
AD  - Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UK.
AD  - Institute of Systems, Molecular and Integrative Biology, University of Liverpool, 
      Liverpool, UK.
FAU - Tennant, A
AU  - Tennant A
AD  - Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 
      Leeds, UK.
CN  - Tonic Study Group
LA  - eng
GR  - MR/L501529/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/R024804/1/MRC_/Medical Research Council/United Kingdom
GR  - YOUNG/JAN15/929-794/MNDA_/Motor Neurone Disease Association/United Kingdom
PT  - Journal Article
DEP - 20220906
PL  - England
TA  - Amyotroph Lateral Scler Frontotemporal Degener
JT  - Amyotrophic lateral sclerosis & frontotemporal degeneration
JID - 101587185
SB  - IM
MH  - Humans
MH  - Male
MH  - Aged
MH  - Female
MH  - *Amyotrophic Lateral Sclerosis/diagnosis
MH  - Depression
MH  - Prevalence
MH  - Anxiety
MH  - Cross-Sectional Studies
OTO - NOTNLM
OT  - Amyotrophic lateral sclerosis
OT  - antidepressants
OT  - depression prevalence
OT  - epidemiology
OT  - models
OT  - modified-hospital anxiety and depression scale
OT  - prognostic
OT  - trajectories of outcome in neurological conditions (TONiC-ALS)
EDAT- 2022/09/07 06:00
MHDA- 2023/01/26 06:00
CRDT- 2022/09/06 07:52
PHST- 2022/09/07 06:00 [pubmed]
PHST- 2023/01/26 06:00 [medline]
PHST- 2022/09/06 07:52 [entrez]
AID - 10.1080/21678421.2022.2096410 [doi]
PST - ppublish
SO  - Amyotroph Lateral Scler Frontotemporal Degener. 2023 Feb;24(1-2):82-90. doi: 
      10.1080/21678421.2022.2096410. Epub 2022 Sep 6.